A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to evaluate the feasibility of undertaking a Phase 0
surgical study in patients with diagnosis of a IDH1 mutated Low Grade Glioma (LGG) who have
not received prior radiation or chemotherapy and are planned to undergo surgical resection.
Phase:
Early Phase 1
Details
Lead Sponsor:
Melbourne Health
Collaborators:
AnHeart Therapeutics Inc. Walter and Eliza Hall Institute of Medical Research